CDK4 and cancer: In addition, numerous clinical trials are performed with this combinatorial treatment in various cancer types by using ribociclib, palbociclib, abemaciclib or dalpiciclib as CDK4/6 inhibitors and different MAPK inhibitors (Table 1).